

FEB. 1. 2006 2:38PM

AVENTIS US PAT DEPT

NO. 1572 P. 3
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
E. Kostenis et al.

Examiner: S. Priebe

RECEIVED
CENTRAL FAX CENTER

Application No.: 10/706,763

Art Unit: 1633

FEB 01 2006

Filed: November 12, 2003

TELEFAX CERTIFICATE

Title: Use of EDG2 Receptor in An Animal Model
of Heart Failure

I hereby certify that this correspondence is being
transmitted via facsimile to the Commissioner for Patents,
Alexandria, VA 22313, on

Feb 1, 2006
Date of Transmission
Signature Dulsi Conque

RESPONSE TO OFFICE COMMUNICATION


Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In response to the Office Communication dated October 20, 2005 in the above-referenced application, applicants elect Group I, claims 1-8, drawn to mammalian myocardial cells transfected with an adenoviral vector encoding EDG2 and a marker, classified in class 435, subclass 325. Applicants reserve the right to file one or more divisional applications directed to the non-elected subject matter in this application.

A request for a three-month extension of time and the required fee accompany this amendment, extending the period of reply to February 20, 2006. The Commissioner is authorized to charge the \$1020 (three-month extension fee) or any additional fees or credit any overpayment necessitated by this response to Deposit Account No. 18-1982.

Respectfully submitted,


Xuhong Sunny Wang, Reg. No. 54,524
Patent Agent for Applicant

Sanofi-Aventis Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807
Telephone (908) 231-3648
Telefax (908) 231-2626
Docket No. DEAV2002/0083 US NP